2023 World Conference on Lung Cancer (Posters)-P2.09. A Large Asian Real-World EGFR exon 20Insertion Mutated NSCLC Dataset with Deep Genomic Characterization

P2.09. A Large Asian Real-World EGFR exon 20Insertion Mutated NSCLC Dataset with Deep Genomic Characterization - PDF(Slides)

Back to course

Pdf Summary

This document presents a study on the clinicopathologic and genomic characterization of EGFR exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC) in Asia. The study analyzed the clinicopathologic features and outcomes of 136 patients with EGFR ex20ins mutations, and compared them to EGFR ex19del/L858R mutations. The prevalence of EGFR ex20ins mutations was found to be 4.6% among non-squamous NSCLC patients.<br /><br />The study found that patients with EGFR ex20ins mutations had limited responses to standard therapies. Genomic characterization revealed that ex20ins mutations have comparable features to ex19del/L858R mutations, but remain a molecular subtype with high unmet need. There were no significant differences observed in median tumor mutational burden, number of cancer driver co-mutations, TP53 co-mutations, whole genome doubling, or genomic instability index between ex20ins and ex19del/L858R mutations.<br /><br />In terms of treatment, the study showed that responses to first to third generation EGFR tyrosine kinase inhibitor (TKI) therapy were limited, but varied depending on the location of the ex20ins variant. The study also analyzed the response rates to EGFR TKIs according to the generation of TKI and the location of the ex20ins variant.<br /><br />Overall, this study provides a comprehensive analysis of the clinicopathologic and genomic characteristics of EGFR ex20ins mutated NSCLC in Asia. It highlights the limited responses to standard therapies and the need for further research and targeted therapeutic approaches for this molecular subtype.

Asset Subtitle

Aaron Tan

Meta Tag

Speaker Aaron Tan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

clinicopathologic

genomic characterization

EGFR exon 20 insertion

ex20ins mutated NSCLC

Asia

limited responses

molecular subtype

tumor mutational burden

EGFR TKI therapy

targeted therapeutic approaches